Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 adjusted EPS and FY2026 sales guidance. Also, the company announced a new $1 billion share buyback program.

HALO

IBBQ

SBIO

LABU

<p>Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 adjusted EPS and FY2026 sales guidance. Also, the company announced a new $1 billion share buyback program.</p>

benzinga_article

Halozyme Therap

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

News